| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8790539 | American Journal of Ophthalmology | 2018 | 12 Pages |
Abstract
The cost savings from the use of bevacizumab from 2008 to 2015 for Medicare fee-for-service patients undergoing treatment for exudative AMD was estimated at $17.3 billion. Additional savings over the $17.3 billion would have accrued from the use of bevacizumab if diagnostic categories such as diabetic macular edema and retinal vein occlusion were included in this study.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Philip J. Rosenfeld, Matthew A. Windsor, William J. Feuer, Sissi J.J. Sun, Kevin D. Frick, Eric A. Swanson, David Huang,